Finasteride and Minoxidil Interaction: Synergistic | Peptide Database

Join others researching Nandrolone — share findings, ask questions, and learn from real experiences Nandrolone is a synthetic 19-nortestosterone anabolic-androgenic steroid that has been in clinical use since the 1960s. Structurally, it differs from testosterone by the absence of a methyl group at the C19 position, which significantly reduces its androgenic activity relative to its anabolic potency. Nandrolone decanoate (Deca-Durabolin) was FDA-approved for the treatment of anemia associated with chronic renal failure and has also been used clinically for osteoporosis, wasting diseases, and severe burn recovery. Among anabolic steroids, nandrolone is particularly valued for its positive effects on collagen synthesis, joint health, and bone mineral density. It has one of the most favorable anabolic-to-androgenic ratios of any synthetic steroid (approximately 125:37 compared to testosterone at 100:100), making it a frequent choice for individuals seeking muscle growth with reduced androgenic side effects. Nandrolone is available in two primary ester formulations: the long-acting decanoate ester and the shorter-acting phenylpropionate ester (NPP). Nandrolone binds to the androgen receptor (AR) with affinity comparable to testosterone, promoting nitrogen retention, protein synthesis, and satellite cell activation in skeletal muscle tissue. Its anabolic effects are mediated through AR-dependent gene transcription that upregulates muscle-specific proteins including myosin heavy chain and IGF-1. A key distinguishing feature of nandrolone is its interaction with 5-alpha reductase: unlike testosterone, which is converted to the more potent androgen dihydrotestosterone (DHT), nandrolone is reduced to dihydronandrolone (DHN), a weaker androgen. This results in lower androgenic activity in tissues rich in 5-alpha reductase (skin, prostate, hair follicles). Nandrolone also stimulates collagen synthesis and bone mineral content through direct effects on osteoblasts and fibroblasts, contributing to its well-documented benefits for joint and connective tissue health. It exhibits moderate progestogenic activity, binding to the progesterone receptor at approximately 20% the affinity of progesterone, which can influence prolactin levels and contribute to progesterone-related side effects. Nandrolone aromatizes to estradiol at roughly 20% the rate of testosterone, resulting in lower but not absent estrogenic activity.

Join others researching Ezetimibe — share findings, ask questions, and learn from real experiences Ezetimibe is a selective cholesterol absorption inhibitor that blocks the Niemann-Pick C1-Like 1 (NPC1L1) protein in the brush border of the small intestine, preventing dietary and biliary cholesterol from entering the bloodstream. Approved by the FDA in 2002, it occupies a unique niche among lipid-lowering agents by targeting intestinal cholesterol uptake rather than hepatic cholesterol synthesis. In the context of anabolic steroid use, ezetimibe has become a go-to ancillary compound for managing the dyslipidemia that accompanies many AAS cycles, particularly oral steroids like oxandrolone (Anavar) and stanozolol (Winstrol) that are notorious for crashing HDL cholesterol and elevating LDL. While statins remain the first-line treatment for hypercholesterolemia in the general population, ezetimibe is frequently used alone or stacked with a statin by steroid users seeking to mitigate cycle-induced lipid damage without adding yet another hepatotoxic compound to the mix. Ezetimibe selectively inhibits the NPC1L1 transporter protein located on the luminal surface of enterocytes in the jejunum of the small intestine. NPC1L1 is the critical gateway for intestinal cholesterol absorption, responsible for uptaking both dietary cholesterol and the much larger pool of biliary cholesterol that is recirculated through the enterohepatic cycle. By blocking this transporter, ezetimibe reduces cholesterol delivery to the liver, which in turn upregulates hepatic LDL receptor expression to compensate for the reduced cholesterol supply. This upregulation increases LDL clearance from the bloodstream. The mechanism is entirely complementary to statins, which inhibit HMG-CoA reductase to reduce hepatic cholesterol synthesis. When the liver is deprived of cholesterol from both sources simultaneously, the LDL-lowering effect is significantly amplified. Ezetimibe undergoes glucuronidation in the intestinal wall and liver to form its active metabolite, ezetimibe-glucuronide, which is also pharmacologically active and participates in enterohepatic recirculation, contributing to the drug's prolonged duration of action.